RemeGen Co (9995.HK) Stock Price
RemeGen Co Price
Revenue has compounded at 124.5% per year over the past 7 years to 3.76 B CNY. RemeGen Co's net margin stands at 21.8%, up from 19.4% several years earlier. The stock trades about 41% above its 52-week low.
RemeGen Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of RemeGen Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how RemeGen Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing RemeGen Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | RemeGen Co Price |
|---|---|
| 9/9/2026 | 77.95 CNY |
| 9/8/2026 | 78.00 CNY |
| 9/7/2026 | 67.41 CNY |
| 9/4/2026 | 69.13 CNY |
| 9/3/2026 | 69.73 CNY |
| 9/2/2026 | 68.33 CNY |
| 9/1/2026 | 68.12 CNY |
| 8/31/2026 | 69.34 CNY |
| 8/28/2026 | 71.96 CNY |
| 8/27/2026 | 70.85 CNY |
| 8/26/2026 | 69.04 CNY |
| 8/25/2026 | 68.96 CNY |
| 8/24/2026 | 63.63 CNY |
| 8/21/2026 | 67.78 CNY |
| 8/20/2026 | 68.79 CNY |
| 8/19/2026 | 66.95 CNY |
| 8/18/2026 | 68.07 CNY |
| 8/17/2026 | 69.86 CNY |
| 8/14/2026 | 69.44 CNY |
| 8/13/2026 | 71.00 CNY |
| 8/12/2026 | 73.12 CNY |
| 8/11/2026 | 72.00 CNY |
| 8/10/2026 | 74.52 CNY |
| 8/7/2026 | 74.33 CNY |
| 8/6/2026 | 68.85 CNY |
| 8/5/2026 | 71.16 CNY |
| 8/4/2026 | 69.43 CNY |
| 8/3/2026 | 67.74 CNY |
| 7/31/2026 | 71.54 CNY |
| 7/30/2026 | 68.65 CNY |
RemeGen Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
RemeGen Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB CNY |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB CNY |
| EBITB CNY |
| EBIT MARGIN% |
| NET INCOMEB CNY |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | – | – | 1.65 | 0.89 | 1.25 | 1.98 | 3.76 | 5.52 | 5.73 | 8.04 | 8.21 | 11.61 |
| – | -76.92 | – | – | -45.78 | 40.25 | 58.59 | 89.36 | 46.95 | 3.75 | 40.28 | 2.12 | 41.45 |
| 15.38 | -1,633.33 | – | 95.26 | 64.69 | 76.26 | 79.79 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| – | -0.05 | -0.09 | 1.57 | 0.58 | 0.95 | 1.58 | 3.76 | 5.52 | 5.73 | 8.04 | 8.21 | 11.61 |
| -0.28 | -0.45 | -0.82 | 0.19 | -1.15 | -1.74 | -1.63 | 0.83 | 0.83 | 1.78 | 5.35 | -4.26 | – |
| -2,161.54 | -14,866.67 | – | 11.43 | -128.92 | -138.69 | -81.91 | 22.17 | 14.96 | 31.08 | 66.52 | -51.87 | – |
| -0.31 | -0.50 | -0.81 | 0.32 | -1.15 | -1.75 | -1.70 | 0.82 | 0.68 | 1.47 | 4.09 | – | – |
| – | 59.81 | 62.17 | -139.58 | -461.76 | 51.30 | -2.86 | -148.23 | -17.11 | 116.08 | 179.32 | – | – |
| 478.36 | 478.36 | 489.84 | 485.39 | 556.35 | 540.18 | 536.23 | 547.49 | 547.49 | 547.49 | 547.49 | 547.49 | 547.49 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales RemeGen Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue RemeGen Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare RemeGen Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares RemeGen Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against RemeGen Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
RemeGen Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
RemeGen Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
RemeGen Co business model & stock analysis
RemeGen Co SWOT Analysis
Strengths
- Strong Research and Development Capabilities
- RemeGen Co Ltd possesses a robust research and development team that excels in creating innovative and effective pharmaceutical products. Their expertise and dedication enable the company to develop cutting-edge medicines to address critical medical conditions.
- Diverse Product Portfolio
- The company boasts a wide range of pharmaceutical products in various therapeutic areas. This diversified portfolio helps RemeGen Co Ltd capture a larger customer base and reduces its reliance on a single product or market segment.
- Strong Market Presence in Domestic Market
- RemeGen Co Ltd has established a strong presence in its domestic market. Their extensive distribution network, coupled with effective marketing strategies, has enabled them to capture a significant market share and maintain competitive advantages in their home country.
Weaknesses
- Limited Global Market Penetration
- Despite its success in the domestic market, RemeGen Co Ltd has yet to expand its presence significantly in international markets. Their limited global market penetration increases vulnerability to economic fluctuations or regulatory changes in the domestic market.
- Reliance on External Manufacturing
- The company relies on external manufacturing partners for a significant portion of its production capacity. This dependency introduces potential risks such as quality control issues, supply chain disruptions, and increased manufacturing costs.
- Limited Brand Recognition
- RemeGen Co Ltd faces a challenge in building strong brand recognition outside its domestic market. Limited brand awareness may hinder their ability to compete against well-established global pharmaceutical companies in international markets.
Opportunities
- Expansion into Emerging Markets
- With their strong product portfolio, RemeGen Co Ltd can consider entering emerging markets with high growth potential. Expanding into these markets can help diversify revenue sources, reduce reliance on the domestic market, and tap into new customer segments.
- Strategic Partnerships and Collaborations
- Forming strategic alliances and collaborations with other pharmaceutical companies can provide RemeGen Co Ltd with access to new technologies, markets, and resources. Such partnerships can enhance the company's capabilities, accelerate product development, and strengthen its competitive position.
- Increased Focus on Research and Development
- Investing further in research and development can enable RemeGen Co Ltd to continuously enhance its product pipeline and bring forth new breakthrough treatments. This focus on innovation can help the company maintain a competitive edge in the pharmaceutical industry.
Threats
- Intense Competition in the Pharmaceutical Industry
- RemeGen Co Ltd operates in a highly competitive environment characterized by the presence of both global pharmaceutical giants and local players. Intense competition can erode market share, lead to price pressures, and necessitate substantial marketing efforts to differentiate themselves.
- Stringent Regulatory Requirements
- The pharmaceutical industry faces rigorous regulations and strict compliance requirements, making it essential for RemeGen Co Ltd to stay up-to-date with changing regulations across markets. Non-compliance or delays in obtaining regulatory approvals can significantly impact product launches and revenue generation.
- Economic Uncertainty
- Economic uncertainties, such as recessions or financial crises, can impact consumer purchasing power and healthcare spending. RemeGen Co Ltd must navigate and adapt to changing economic conditions to ensure sustained demand for their products.
RemeGen Co Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
RemeGen Co historical P/E ratio, EBIT multiple, and P/S ratio
RemeGen Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
RemeGen Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
EESG©
Eulerpool ESG Scorecard© for the RemeGen Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
RemeGen Co shareholder structure
| % | Name |
|---|---|
1.08308% | |
0.18496% | |
0.14882% | |
0.01443% | |
0.00431% | |
0.00193% |
RemeGen Co Beneficial Ownership Filings (SEC 13D/G)
RemeGen Co Executives and Management Board
10 members · avg. age 56 · 10 % women
Mr. Jianmin Fang (62)
Chief Executive Officer, Chief Scientific Officer, General Manager, Executive Director · since 2008
7.39 M CNY
Management
Mr. Shaojing Tong (53)
Chief Financial Officer, Joint Company Secretary
Board of Directors
Mr. Weidong Wang (65)
Executive Chairman of the Board · since 2013
Mr. Qingkai Wen (58)
Executive Director, Secretary of the Board · since 2020
Mr. Jian Lin (70)
Executive Director · since 2008
Mr. Yunjin Chen (39)
Independent Director
Mr. Xianjing Hao (59)
Independent Director
Ms. Xiaodi Su (38)
Non-Executive Director
Frequently asked questions about RemeGen Co
RemeGen Co Ltd is a biopharmaceutical company based in China. The business model of RemeGen Co Ltd primarily focuses on the research, development, and commercialization of innovative biologics for the treatment of various diseases. The company specializes in developing monoclonal antibodies and fusion proteins to target specific diseases, such as cancer and autoimmune disorders. RemeGen Co Ltd aims to provide effective and safe therapeutic options to patients in need, while also generating sustainable growth and creating value for its shareholders. With its dedication to advancing healthcare through biotechnology, RemeGen Co Ltd strives to positively impact patients' lives and contribute to the advancement of the global pharmaceutical industry.
RemeGen Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of RemeGen Co Ltd in the market include a range of pharmaceutical companies operating in the same sector. Some notable competitors include BeiGene Ltd, Hengrui Medicine Co Ltd, and Junshi Biosciences Co Ltd. These companies, like RemeGen Co Ltd, are engaged in the research, development, and commercialization of innovative drugs and therapies. As a leading player in the pharmaceutical industry, RemeGen Co Ltd competes in various therapeutic areas, aiming to bring novel and effective treatments to the market.
RemeGen Co Ltd is a renowned biopharmaceutical company founded in 2008, headquartered in Yantai, China. With a focus on research, development, and commercialization of innovative therapies, RemeGen has made significant strides in the field of oncology. The company aims to address unmet medical needs and revolutionize treatment options for patients worldwide. RemeGen Co Ltd has earned recognition for its robust pipeline of potential breakthrough drugs, leveraging their expertise in monoclonal antibodies, antibody-drug conjugates, and fusion proteins. Their commitment to scientific excellence and dedication to improving patients' lives have established RemeGen as a leading player in the biopharmaceutical industry.
RemeGen Co Ltd has achieved several significant milestones in its journey. Firstly, the company successfully developed three innovative antibody-based drugs targeting cancer and autoimmune diseases. This breakthrough in biopharmaceutical research highlights RemeGen's commitment to advancing medical treatments. Additionally, the company gained approval for its leading drug, RC48, to treat metastatic or locally recurrent triple-negative breast cancer, a major accomplishment in the field. Moreover, RemeGen forged strategic partnerships with top global pharmaceutical companies, fostering collaborations for research, development, and commercialization of its drugs. These milestones underscore RemeGen Co Ltd's dedication to revolutionizing healthcare and cement its position as a trusted leader in the industry.
RemeGen Co Ltd is primarily present in China.
RemeGen Co Ltd, a leading biopharmaceutical company, is guided by a strong set of values and corporate philosophy. With a focus on innovation, RemeGen strives to develop and deliver high-quality and cutting-edge therapies to improve the lives of patients. Their commitment to integrity and ethical practices forms the foundation of their operations. RemeGen embraces a patient-centric approach, ensuring that their products address significant medical needs and contribute to the well-being of individuals. By fostering collaboration and nurturing talent, RemeGen places great importance on teamwork and continuous learning. With these values and corporate philosophy, RemeGen Co Ltd remains dedicated to making a positive impact in the healthcare industry.
Converted at the current exchange rate, the RemeGen Co share trades at 9.97 EUR (77.95 CNY).
The RemeGen Co share (9995.HK) is listed on 4 stock exchanges, including: Frankfurt (REG.F), Düsseldorf (REG.DU).
The company RemeGen Co Ltd is a biopharmaceutical company based in China that specializes in the development and commercialization of novel therapeutic antibodies. The company was founded in 2008 and is one of the leading companies in the biopharmaceutical industry. RemeGen is working on the development of antibodies with high efficacy and low risk of side effects. The company has developed a comprehensive pipeline that includes clinical trials for a variety of diseases, including cancer, autoimmune diseases, viral infections, and inflammation. The company's main product is IBI310, a monoclonal antibody specifically designed for the treatment of cancer patients. IBI310 fights cancer cells by selectively binding to the surface protein PD-L1 and triggering an immune response that destroys the cancer cells. The drug has the potential to revolutionize the treatment of cancer patients and is already being tested in clinical trials. RemeGen also offers projects in the field of novel antibody therapy for autoimmune diseases. The company has developed a pipeline of several potential therapeutics targeting various target molecules involved in autoimmune diseases. The company is also focused on the development of drugs to combat viral infections such as hepatitis B and C, as well as HIV. RemeGen's goal is to defeat these diseases and provide patients with a better quality of life. RemeGen is also a leading provider of biopharmaceutical services that support customers in conducting their research and product development. The company offers a wide range of services ranging from antibody design and development to cell line development and production, as well as analysis and characterization. RemeGen's business model is based on collaboration with other biopharmaceutical companies to jointly develop more innovative and effective therapies. The company has established strong partnerships with leading pharmaceutical companies such as Pfizer, Merck, and Roche. RemeGen's experience and expertise in the field of biopharmaceutical research and development have contributed to its position as one of the leading companies in this field. The company is continuously working to improve medical care and enhance the quality of life for patients.
The revenue cannot currently be calculated for RemeGen Co.
The profit cannot currently be calculated for RemeGen Co.
The P/E ratio cannot be calculated for RemeGen Co at the moment.
The P/S cannot be calculated for RemeGen Co currently.
The Eulerpool Quality Score for RemeGen Co is 4/10.
The ISIN of RemeGen Co is CNE1000048G6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of RemeGen Co is A2QGM4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of RemeGen Co is 9995.HK. The ticker symbol is used to trade RemeGen Co shares on the stock exchange.
RemeGen Co paid dividends every year for the past 0 years.
RemeGen Co is assigned to the 'Health' sector.
The dividends of RemeGen Co are distributed in CNY.
RemeGen Co stock
RemeGen Co Peer Group
RemeGen Co Ticker
RemeGen Co FIGI
All fundamentals and in-depth analysis of RemeGen Co
Our stock analysis for RemeGen Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RemeGen Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.